uniQure to report Q3 2026 earnings on Nov 4, highlighting progress in gene therapy treatments.

uniQure Inc., a gene therapy company, will announce its third quarter 2026 financial results on November 4, 2026, before the market opens. The company will host a conference call at 8:30 a.m. ET to discuss the results and ongoing advancements in gene therapies, including treatments for hemophilia B, Huntington's disease, and other severe conditions. This report is significant as uniQure continues to develop potentially curative single-treatment therapies, marking important progress in genomic medicine. Investors and analysts can join the live call or access a replay on uniQure's website.

uniQure's market capitalization stands at $1.68 billion as of October 28, 2026, 18:21 WIB, reflecting its significant presence in the health sector. The stock trades at $24.37 on Pluang, showing a modest 0.37% increase in the past day. Trading volume is active, with 1,570,986 shares exchanged, and investors typically hold the stock for about 8 days. This data provides context for the upcoming third quarter financial results announcement on November 4, 2026.